Novel insulin receptor substrate 1 and 2 variants in breast and colorectal cancer
about
The Insulin/IGF System in Colorectal Cancer Development and Resistance to TherapyIRS-2 rs1805097 polymorphism is associated with the decreased risk of colorectal cancerSingle nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.Association of IRS2 overexpression with disease progression in intrahepatic cholangiocarcinoma
P2860
Novel insulin receptor substrate 1 and 2 variants in breast and colorectal cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel insulin receptor substrate 1 and 2 variants in breast and colorectal cancer
@en
Novel insulin receptor substrate 1 and 2 variants in breast and colorectal cancer.
@nl
type
label
Novel insulin receptor substrate 1 and 2 variants in breast and colorectal cancer
@en
Novel insulin receptor substrate 1 and 2 variants in breast and colorectal cancer.
@nl
prefLabel
Novel insulin receptor substrate 1 and 2 variants in breast and colorectal cancer
@en
Novel insulin receptor substrate 1 and 2 variants in breast and colorectal cancer.
@nl
P2093
P2860
P356
P1433
P1476
Novel insulin receptor substrate 1 and 2 variants in breast and colorectal cancer
@en
P2093
Alessandro Cama
Antonio Russo
Cinzia Vanni
Diana Liberata Esposito
Fabio Verginelli
Laura De Lellis
Sandra Mammarella
Sonia Toracchio
P2860
P304
P356
10.3892/OR.2013.2626
P577
2013-07-18T00:00:00Z